See more : Canadian Net Real Estate Investment Trust (CNNRF) Income Statement Analysis – Financial Results
Complete financial analysis of Teleflex Incorporated (TFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teleflex Incorporated, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Anavex Life Sciences Corp. (0HFR.L) Income Statement Analysis – Financial Results
- BW LPG Limited (0QIX.L) Income Statement Analysis – Financial Results
- Decklar Resources Inc. (DKL.V) Income Statement Analysis – Financial Results
- Modern Chinese Medicine Group Co., Ltd. (1643.HK) Income Statement Analysis – Financial Results
- Photozou Holdings, Inc. (PTZH) Income Statement Analysis – Financial Results
Teleflex Incorporated (TFX)
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.97B | 2.79B | 2.81B | 2.54B | 2.60B | 2.45B | 2.15B | 1.87B | 1.81B | 1.84B | 1.70B | 1.55B | 1.53B | 1.80B | 1.89B | 2.42B | 1.93B | 2.65B | 2.51B | 2.49B | 2.28B | 2.08B | 1.91B | 1.76B | 1.60B | 1.44B | 1.15B | 931.20M | 912.70M | 812.70M | 666.80M | 567.10M | 479.50M | 441.10M | 355.60M | 328.20M | 269.80M | 214.20M | 171.80M |
| Cost of Revenue | 1.33B | 1.26B | 1.26B | 1.21B | 1.10B | 1.06B | 974.50M | 871.83M | 865.29M | 897.40M | 857.33M | 802.78M | 810.07M | 1.01B | 1.08B | 1.46B | 1.25B | 1.87B | 1.80B | 1.79B | 1.68B | 1.52B | 1.37B | 1.20B | 1.09B | 969.60M | 746.90M | 601.40M | 590.30M | 524.40M | 431.00M | 360.40M | 311.80M | 286.90M | 237.20M | 215.50M | 175.80M | 140.50M | 114.70M |
| Gross Profit | 1.65B | 1.53B | 1.55B | 1.32B | 1.49B | 1.38B | 1.17B | 996.20M | 944.40M | 942.43M | 838.95M | 748.23M | 718.84M | 794.07M | 814.08M | 964.17M | 680.35M | 774.19M | 709.95M | 698.80M | 597.79M | 552.45M | 535.29M | 567.70M | 512.60M | 468.00M | 398.90M | 329.80M | 322.40M | 288.30M | 235.80M | 206.70M | 167.70M | 154.20M | 118.40M | 112.70M | 94.00M | 73.70M | 57.10M |
| Gross Profit Ratio | 55.37% | 54.86% | 55.15% | 52.22% | 57.47% | 56.55% | 54.60% | 53.33% | 52.19% | 51.22% | 49.46% | 48.24% | 47.02% | 44.07% | 43.07% | 39.83% | 35.17% | 29.25% | 28.23% | 28.12% | 26.19% | 26.61% | 28.10% | 32.17% | 32.02% | 32.55% | 34.81% | 35.42% | 35.32% | 35.47% | 35.36% | 36.45% | 34.97% | 34.96% | 33.30% | 34.34% | 34.84% | 34.41% | 33.24% |
| Research & Development | 154.35M | 153.82M | 130.84M | 119.75M | 113.86M | 106.21M | 84.77M | 58.58M | 52.12M | 61.04M | 65.05M | 56.28M | 48.73M | 42.62M | 0.00 | 0.00 | 30.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 991.05M | 863.75M | 860.09M | 743.57M | 934.37M | 878.69M | 699.96M | 563.31M | 568.98M | 578.66M | 502.19M | 454.49M | 429.26M | 475.32M | 519.93M | 596.77M | 445.25M | 493.52M | 449.04M | 494.43M | 423.03M | 365.02M | 347.13M | 311.28M | 284.70M | 266.10M | 230.20M | 190.30M | 192.40M | 173.90M | 141.00M | 124.20M | 93.70M | 84.80M | 63.90M | 59.10M | 49.60M | 39.80M | 31.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 582.00K | -341.00K | 2.60M | 2.34M | 0.00 | 838.00K | -14.22M | -2.73M | -1.93B | -18.90M | 0.00 | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| Operating Expenses | 1.14B | 1.02B | 990.93M | 863.32M | 1.05B | 984.90M | 784.73M | 621.89M | 621.10M | 639.70M | 567.23M | 510.77M | 478.58M | 517.60M | 522.52M | 624.18M | 445.25M | 494.35M | 434.82M | 491.70M | -1.51B | 346.12M | 347.13M | 388.70M | 352.10M | 326.20M | 278.10M | 229.10M | 230.10M | 206.90M | 169.10M | 145.80M | 112.10M | 102.00M | 76.80M | 70.10M | 59.40M | 47.00M | 36.50M |
| Cost & Expenses | 2.47B | 2.28B | 2.25B | 2.08B | 2.15B | 2.05B | 1.76B | 1.49B | 1.49B | 1.54B | 1.42B | 1.31B | 1.29B | 1.53B | 1.60B | 2.08B | 1.70B | 2.37B | 2.24B | 2.28B | 177.83M | 1.87B | 1.72B | 1.59B | 1.44B | 1.30B | 1.03B | 830.50M | 820.40M | 731.30M | 600.10M | 506.20M | 423.90M | 388.90M | 314.00M | 285.60M | 235.20M | 187.50M | 151.20M |
| Interest Income | 12.78M | 912.00K | 1.33M | 1.16M | 1.74M | 944.00K | 771.00K | 474.00K | 532.00K | 706.00K | 624.00K | 1.57M | 1.26M | 861.00K | 2.54M | 2.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 85.08M | 54.26M | 56.97M | 66.49M | 80.27M | 103.02M | 82.55M | 54.94M | 61.32M | 65.46M | 56.91M | 69.57M | 70.32M | 80.03M | 89.46M | 121.65M | 0.00 | 0.00 | 0.00 | 37.12M | 26.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.12M | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M | 155.26M | 117.91M | 108.39M | 111.13M | 92.98M | 80.47M | 85.62M | 92.19M | 101.06M | 111.22M | 78.76M | 99.00M | 100.85M | 114.60M | 104.35M | 95.12M | 92.40M | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| EBITDA | 761.21M | 751.65M | 873.10M | 665.98M | 634.24M | 532.63M | 522.72M | 418.57M | 414.36M | 396.70M | 325.61M | -26.39M | 288.87M | 302.71M | 353.78M | 453.84M | 313.86M | 309.20M | 284.14M | 308.41M | 302.80M | 307.27M | 280.56M | 256.42M | 227.90M | 201.90M | 168.70M | 139.50M | 130.00M | 114.40M | 94.80M | 82.50M | 74.00M | 69.40M | 54.50M | 53.60M | 44.40M | 33.90M | 25.40M |
| EBITDA Ratio | 25.59% | 26.69% | 28.38% | 27.19% | 25.40% | 24.93% | 25.30% | 26.38% | 23.88% | 22.53% | 21.54% | 20.60% | 15.80% | 20.51% | 20.91% | 18.75% | 19.40% | 15.30% | 15.46% | 15.55% | 96.65% | 14.03% | 14.73% | 14.53% | 14.23% | 14.04% | 14.72% | 14.98% | 14.24% | 14.08% | 14.22% | 13.98% | 14.70% | 15.03% | 14.09% | 16.33% | 15.72% | 13.96% | 12.92% |
| Operating Income | 506.31M | 499.73M | 628.10M | 423.07M | 427.25M | 321.70M | 372.28M | 319.45M | 315.89M | 284.86M | 233.26M | -97.38M | 233.17M | 273.59M | 269.77M | 339.99M | 192.64M | 254.61M | 248.07M | 139.49M | 2.10B | 206.33M | 188.16M | 179.00M | 160.50M | 141.80M | 120.80M | 100.70M | 92.30M | 81.40M | 66.70M | 60.90M | 55.60M | 52.20M | 41.60M | 42.60M | 34.60M | 26.70M | 20.60M |
| Operating Income Ratio | 17.02% | 17.90% | 22.36% | 16.67% | 16.46% | 13.14% | 17.35% | 17.10% | 17.46% | 15.48% | 13.75% | -6.28% | 15.25% | 15.19% | 14.27% | 14.04% | 9.96% | 9.62% | 9.87% | 5.61% | 92.21% | 9.94% | 9.88% | 10.14% | 10.02% | 9.86% | 10.54% | 10.81% | 10.11% | 10.02% | 10.00% | 10.74% | 11.60% | 11.83% | 11.70% | 12.98% | 12.82% | 12.46% | 11.99% |
| Total Other Income/Expenses | -72.30M | -53.81M | -68.63M | -65.34M | -122.08M | 23.20M | -87.37M | -73.73M | -71.25M | -64.75M | -57.53M | -181.78M | -84.47M | -82.50M | -86.92M | -119.01M | -83.29M | -35.93M | -39.67M | -42.35M | -23.27M | -33.84M | -28.47M | -20.79M | -17.77M | -16.98M | -14.40M | -13.90M | -18.70M | -18.40M | -14.40M | -12.30M | -10.30M | -9.30M | -2.40M | -6.20M | -2.90M | 200.00K | 1.60M |
| Income Before Tax | 434.01M | 445.92M | 559.47M | 357.73M | 339.90M | 219.63M | 284.91M | 245.73M | 244.65M | 220.11M | 175.73M | -165.37M | 148.70M | 147.79M | 182.85M | 220.98M | 109.35M | 219.03M | 207.92M | 102.37M | 151.49M | 172.49M | 159.70M | 158.21M | 142.70M | 124.80M | 106.40M | 86.80M | 73.60M | 63.00M | 52.30M | 48.60M | 45.30M | 42.90M | 39.20M | 36.40M | 31.70M | 26.90M | 22.20M |
| Income Before Tax Ratio | 14.59% | 15.98% | 19.91% | 14.10% | 13.10% | 8.97% | 13.27% | 13.15% | 13.52% | 11.96% | 10.36% | -10.66% | 9.73% | 8.20% | 9.67% | 9.13% | 5.65% | 8.28% | 8.27% | 4.12% | 6.64% | 8.31% | 8.38% | 8.97% | 8.91% | 8.68% | 9.29% | 9.32% | 8.06% | 7.75% | 7.84% | 8.57% | 9.45% | 9.73% | 11.02% | 11.09% | 11.75% | 12.56% | 12.92% |
| Income Tax Expense | 76.44M | 83.00M | 74.35M | 21.93M | -122.08M | 23.20M | 129.65M | 8.07M | 7.84M | 28.65M | 23.55M | 16.41M | 27.00M | 21.89M | 39.90M | 52.17M | 122.77M | 54.14M | 47.81M | 14.35M | 42.39M | 47.22M | 47.38M | 48.99M | 47.50M | 42.20M | 36.30M | 29.60M | 24.70M | 21.80M | 18.60M | 16.60M | 15.50M | 14.30M | 12.40M | 12.40M | 12.00M | 10.50M | 8.90M |
| Net Income | 356.33M | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M | 152.53M | 237.38M | 244.86M | 187.68M | 150.88M | -190.06M | 323.33M | 201.09M | 302.99M | 119.77M | 146.48M | 139.43M | 138.82M | 9.52M | 109.10M | 125.27M | 112.31M | 109.22M | 95.20M | 82.60M | 70.10M | 57.20M | 48.90M | 41.20M | 33.70M | 32.90M | 29.80M | 28.60M | 26.80M | 24.00M | 19.70M | 16.40M | 13.30M |
| Net Income Ratio | 11.98% | 13.01% | 17.28% | 13.22% | 17.78% | 8.20% | 7.11% | 12.71% | 13.53% | 10.20% | 8.89% | -12.25% | 21.15% | 11.16% | 16.03% | 4.95% | 7.57% | 5.27% | 5.52% | 0.38% | 4.78% | 6.03% | 5.90% | 6.19% | 5.95% | 5.75% | 6.12% | 6.14% | 5.36% | 5.07% | 5.05% | 5.80% | 6.21% | 6.48% | 7.54% | 7.31% | 7.30% | 7.66% | 7.74% |
| EPS | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | 3.39 | 5.48 | 5.89 | 4.54 | 3.67 | -4.65 | 7.98 | 5.04 | 7.63 | 3.03 | 3.73 | 3.51 | 3.43 | 0.24 | 2.76 | 3.12 | 2.90 | 2.86 | 2.52 | 2.21 | 1.91 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| EPS Diluted | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | 3.27 | 4.98 | 5.10 | 4.04 | 3.45 | -4.65 | 7.92 | 4.99 | 7.59 | 3.01 | 3.73 | 3.49 | 3.39 | 0.24 | 2.73 | 3.08 | 2.86 | 2.83 | 2.47 | 2.15 | 1.86 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| Weighted Avg Shares Out | 46.98M | 46.90M | 46.77M | 46.49M | 46.20M | 45.69M | 45.00M | 43.33M | 41.56M | 41.37M | 41.11M | 40.86M | 40.50M | 39.91M | 39.72M | 39.58M | 39.26M | 39.76M | 40.52M | 40.21M | 39.60M | 40.15M | 38.73M | 38.19M | 37.78M | 37.38M | 36.70M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
| Weighted Avg Shares Out (Dil) | 47.30M | 47.31M | 47.43M | 47.29M | 47.09M | 46.80M | 46.66M | 47.65M | 48.06M | 46.47M | 43.69M | 40.86M | 40.80M | 40.28M | 39.94M | 39.83M | 39.26M | 39.99M | 40.96M | 40.50M | 39.94M | 40.67M | 39.27M | 38.60M | 38.54M | 38.42M | 37.69M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
TFX or EW: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Teleflex (TFX) or Edwards Lifesciences (EW). But which of these two companies is the best option for those looking for undervalued stocks?
TFX or EW: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now?
Why Teleflex (TFX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook
Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.
Teleflex Incorporated (TFX) Q2 2024 Earnings Call Transcript
Teleflex Incorporated (NYSE:TFX ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Lawrence Keusch - Vice President-Investor Relations & Strategy Development Liam Kelly - Chairman, President & Chief Executive Officer Thomas Powell - Executive Vice...
Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
Teleflex (TFX) Q2 Earnings Surpass Estimates
Teleflex (TFX) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.33 per share. This compares to earnings of $3.41 per share a year ago.
Teleflex raises 2024 profit forecast on medical device demand
Surgical equipment maker Teleflex raised its annual profit forecast on Thursday, banking on resilient demand for certain surgical procedures at hospitals to drive sales for its medical devices.
Teleflex Announces Quarterly Dividend
WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024,...
Teleflex Reports Second Quarter Financial Results and Full Year 2024 Outlook
Announces $500 million share repurchase authorization inclusive of a $200 million accelerated share repurchase of common stock Announces $500 million share repurchase authorization inclusive of a $200 million accelerated share repurchase of common stock
Source: https://incomestatements.info
Category: Stock Reports